ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "ACPA"

  • Abstract Number: 1458 • 2018 ACR/ARHP Annual Meeting

    Impact of the Joint Presence of Erosions and ACPA on Rheumatoid Arthritis Disease Activity over Time: Results from the Meteor Registry

    Sytske Anne Bergstra1, Maura Couto2, Nimmisha Govind3, Arvind Chopra4, Karen Salomon-Escoto5, Elizabeth Murphy6, Tom W.J. Huizinga1 and Cornelia F. Allaart1, 1Department of Rheumatology, LUMC, Leiden, Netherlands, 2Hospital Sao Teotónio, Viseu, Portugal, Viseu, Portugal, 3University of the Witwatersrand, Johannesburg, South Africa, 4Center for Rheumatic Diseases, Pune, India, 5University of Massachusetts Medical School, Rheumatology Center, UMass Memorial Medical Center, Worcester, MA, 6University Hospital Wishaw, Scotland, Wishaw, United Kingdom

    Background/Purpose: Despite efforts to predict treatment response, treatment of rheumatoid arthritis (RA) patients remains mostly a case of trial and error. Previous research, mostly in…
  • Abstract Number: 2791 • 2018 ACR/ARHP Annual Meeting

    Characterization of Monoclonal Anti-PAD4 Autoantibodies from Rheumatoid Arthritis Patients: Functional Implications for Citrullination and Disease Progression

    Alejandro Gomez, Sarah Kongpachith, Nithya Lingampalli, Cecilia Cisar and William H. Robinson, Department of Medicine, Stanford University, Stanford, CA

    Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are present in two-thirds of patients with rheumatoid arthritis (RA), and target proteins that have been post-translationally modified by the…
  • Abstract Number: 1463 • 2018 ACR/ARHP Annual Meeting

    Do Anti-Citrullinated Protein Antibodies and Anti-Sjögren’s-Syndrome-Related Antigen a Double Positive Patients with Secondary Sjögren’s Syndrome and RA Have Higher Joint Disease Activity?

    Evo Alemao1, Yogesh Saini2, Ying Bao1, Aarti Rao2, Christine K Iannaccone3, Michelle Frits3, Michael E Weinblatt3 and Nancy A. Shadick3, 1Bristol-Myers Squibb, Princeton, NJ, 2Mu Sigma, Bangalore, India, 3Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Secondary Sjögren’s syndrome (sSS) is considered an extra-articular manifestation of RA and is an autoantibody-mediated condition similar to RA. Thus, patients (pts) with sSS…
  • Abstract Number: 2793 • 2018 ACR/ARHP Annual Meeting

    Molecular Mimicry and Autoimmunity: Anti-P. Gingivalis antibody Response in ACPA-Positive Rheumatoid Arthritis

    Natalia Sherina1, Natalie Sippl1, Lena Israelsson1, Erwan Le Maitre2, Nastya Kharlamova1, Monika Hansson3, Kaja Eriksson4, Tulay Yucel-Lindberg4, Khaled Amara1 and Karin Lundberg1, 1Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, 2Rheumatology Unit, Department of Medicine, Solna,, Karolinska Institutet, Stockholm, Sweden, 3Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 4Division of Periodontology, Department of Dental Medicine, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: The presence of anti-citrullinated protein antibodies (ACPA) is a hallmark of rheumatoid arthritis (RA). ACPAs specifically recognize citrullinated epitopes, a result of a post-translational…
  • Abstract Number: 1466 • 2018 ACR/ARHP Annual Meeting

    Altered Count of NK Cells and Non-Classical Monocyte Subpopulation in the Pre-Clinical Phase of Rheumatoid Arthritis

    Klára Prajzlerová1, Olga Kryštůfková2, Petra Hánová1, Hana Hulejová3, Monika Gregová4, Karel Pavelka4, Jiri Vencovsky1, Ladislav Šenolt5 and Mária Filková1, 1Department of Rheumatology, First Faculty of Medicine, Charles University and Rheumatology Institute, Prague, Czech Republic, Prague, Czech Republic, 2Department of Rheumatology, First Faculty of Medicine, Charles University and Rheumatology Institute, Prague, Czech Republic, prague, Czech Republic, 3Rheumatology Institute, Prague, Czech Republic, Prague, Czech Republic, 4Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 5First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic

    Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are detectable long before the manifestation of rheumatoid arthritis (RA). EULAR provided a clinical definition of individuals with arthralgia suspicious…
  • Abstract Number: 2901 • 2018 ACR/ARHP Annual Meeting

    Sputum Neutrophils from Individuals at-Risk for RA Demonstrate Increased Citrullinated Histone H3 Containing Neutrophil Extracellular Traps That Correlate with Sputum Anti-Cyclic Citrullinated Peptide Antibody Levels

    Yuko Okamoto1, Nickie L. Seto2, Mariana J. Kaplan2, Ashley Visser1, Jill M. Norris3, Kevin D. Deane1, V. Michael Holers4 and M. Kristen Demoruelle1, 1Division of Rheumatology, University of Colorado Denver, Aurora, CO, 2Systemic Autoimmunity Branch, NIAMS/NIH, Bethesda, MD, 3Department of Epidemiology, Colorado School of Public Health, Aurora, CO, 4Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO

    Background/Purpose: Our group previously demonstrated that anti-citrullinated (cit) protein antibodies (ACPA) in the sputum correlate with remnants of neutrophil extracellular traps (NETs) in RA-free subjects…
  • Abstract Number: 492 • 2017 ACR/ARHP Annual Meeting

    Is Leukotoxin_A Produced By Aggregatibacter Actynomycetemcomitans Important for Initiating Autoimmune Responses Underlying Rheumatoid Arthritis?

    Mikhail Volkov1, Jacqueline Dekkers1, Bruno G. Loos2, Sergio Bizzarro2, Tom W.J. Huizinga3, Helle A. Praetorius4, Rene E.M. Toes5 and Diane van der Woude1, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Department of Periodontology, Academic Centre for Dentistry Amsterdam, University of Amsterdam and Vrije Universiteit, Amsterdam, Netherlands, 3Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, 4Department of Biomedicine, Aarhus University, Aarhus, Denmark, 5Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: In a recent publication in Science Translational Medicine, Konig et al. (2016) describe a potential explanation for the link between periodontal infection and RA.…
  • Abstract Number: 2919 • 2017 ACR/ARHP Annual Meeting

    Number and Type of ACPA Fine Specificities Are Correlated to High Resolution Computed Tomography Parenchymal Lungs Changes in Patients with Early Untreated Rheumatoid Arthritis

    Vijay Joshua1, Aase Hensvold1, Gudrun Reynisdottir1, Monika Hansson1, Guy Serre2, Johan Grunewald3, Katerina Chatzidionysiou1 and Anca I. Catrina1, 1Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, 2Unité Différenciation Épidermique et Autoimmunité Rhumatoïde, Unité Mixte de Recherche, INSERM, Toulouse, France, 3Division of Respiratory Medicine, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Airways abnormalities that are consistent with inflammation are common in anti-CCP2 positive subjects without inflammatory arthritis. Anti-CCP2 antibodies are associated with HRCT parenchymal lung…
  • Abstract Number: 836 • 2017 ACR/ARHP Annual Meeting

    B Cell Receptor Sequencing of Anti-Citrullinated Protein Antibody Expressing B Cells Indicates a Selective Advantage for the Introduction of N-Glycosylation Sites during Somatic Hypermutation

    Rochelle D. Vergroesen1, Linda Slot1, Lise Hafkenscheid1, Marvyn T. Koning2, Ellen I.H. van der Voort3, Christine A. Grooff1, George Zervakis2, Tom W.J. Huizinga1, Theo Rispens4, Hendrik Veelken2, Rene E.M. Toes1 and Hans U. Scherer3, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Hematology, Leiden University Medical Center, Leiden, Netherlands, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4Immunopathology, Sanquin Research, Amsterdam, Netherlands

    Background/Purpose: The vast majority (>90%) of anti-citrullinated protein antibodies (ACPA) of the IgG isotype in serum and synovial fluid of patients with rheumatoid arthritis carry…
  • Abstract Number: 970 • 2017 ACR/ARHP Annual Meeting

    ACPA Activate Challenged Synovial Fibroblasts through a PAD Dependent Mechanism: A Potential Explanation of the “Second Hit Model” in RA

    Meng Sun1, Vijay Joshua1, Akilan Krishnamurthy1, Aase Hensvold1, Yanying Liu2, Sergiu-Bogdan Catrina3, Caroline Ospelt4, Vivianne Malmström1, Johanna Steen1, Marianne Engström1, Heidi Wähämaa1, Bence Rethi1 and Anca I. Catrina1, 1Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, 2Rheumatology Unit, Department of Medicine, Peking University People's Hospital, Beijing, China, 3Molecular Medicine and Surgery, Molecular Medicine and Surgery, Stockholm, Sweden, 4Center of Experimental Rheumatology, University Hospital Zürich, Zurich, Switzerland

    Background/Purpose: Anti-citrullinated proteins antibodies (ACPAs) injected in mice induce IL-8 dependent bone loss and arthralgia, but no synovial changes. We hypothesized that additional stimulus, sensitizing…
  • Abstract Number: 990 • 2017 ACR/ARHP Annual Meeting

    Higher Omega-6 to Omega-3 Fatty Acid Ratio Is Associated with Increased Odds of Inflammatory Arthritis in a Health Fair Population Positive for Anti-Citrullinated Protein Antibodies (ACPA)

    Kristen J. Polinski1, Ryan W. Gan2, Elizabeth A. Bemis1, M. Kristen Demoruelle3, Michael J. Clare-Salzler4, V. Michael Holers5, Kevin D. Deane6 and Jill M. Norris7, 1Epidemiology, Colorado School of Public Health, Aurora, CO, 2Colorado School of Public Health, University of Colorado Denver, Aurora, CO, 31775 Aurora Ct, 1775 Aurora Ct, Aurora, CO, 4Experimental Pathology, University of Florida, College of Medicine, Gainesville, FL, 5Rheumatology Division, University of Colorado School of Medicine, Aurora, CO, 6Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 7Department of Epidemiology, Colorado School of Public Health, Aurora, CO

    Background/Purpose: We previously found that lower levels of omega-3 fatty acids (n-3 FA) were associated with the presence of inflammatory arthritis (IA) as well as…
  • Abstract Number: 1250 • 2017 ACR/ARHP Annual Meeting

    Outcomes in Real-World Patients with Early Aggressive Rheumatoid Arthritis

    Keith Knapp1,2, Eric Mueller1,2 and Gary Craig1,2, 1Arthritis Northwest PLLC., Spokane, WA, 2Discus Analytics LLC., Spokane, WA

    Background/Purpose: The window of opportunity to address early rheumatoid arthritis (RA) in patients (pts) is well documented. However early aggressive (agr) RA needs further study…
  • Abstract Number: 1356 • 2017 ACR/ARHP Annual Meeting

    Is ACPA-Positive RA Still a More Severe Disease Than ACPA-Negative RA? a Longitudinal Cohort Study in RA-Patients Treated from 2000 Onwards

    Aleid C. Boer1, Annelies Boonen2 and Annette H.M. van der Helm-van Mil3, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre+, Maastricht, The Netherlands, Maastricht, Netherlands, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Anti-citrullinated-protein antibodies (ACPA)-positive rheumatoid arthritis (RA) is considered as more severe than ACPA-negative RA, because of its association with joint destruction. Clinically relevant joint…
  • Abstract Number: 65 • 2017 ACR/ARHP Annual Meeting

    RA-Associated Antibodies Targeting Post Translational Modification Have Different Osteoclastogenetic Potential

    Akilan Krishnamurthy1, Johanna Steen2, Caroline Grönwall3, Gustaf Wigerblad4, Camilla Svensson5,6, Heidi Wähämaa1, Vivianne Malmström1, Bence Rethi1 and Anca I. Catrina1, 1Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, 2Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 3Dep. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 4Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, 5Dept. of Physiology & Pharmacology, Karolinska Institutet, Stockholm, Sweden, 6Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Some but not all antibodies against citrullinated modified proteins (ACPA) promote osteoclastogenesis and bone destruction in vitro and in vivo. We aimed to investigate…
  • Abstract Number: 1376 • 2017 ACR/ARHP Annual Meeting

    Diagnostic Performance of 7 Different Anti-Cyclic Citrullinated Peptide Antibody and 6 Rheumatoid Factor Assays in a Primary Diagnostic, Consecutive Rheumatological Population in a Secondary Care Hospital

    Lieve Van Hoovels1, Julie Jacobs1, Bert Vander Cruyssen2, Stefanie Van den Bremt1, Patrick Verschueren3 and Xavier Bossuyt4, 1Laboratory medicine, OLV Hospital, Aalst, Belgium, 2Rheumatology, OLV hospital, Aalst, Belgium, 3Division of Rheumatology, University Hospital Leuven, Leuven, Belgium, 4Laboratory medicine, University Hospital Leuven, Leuven, Belgium

    Background/Purpose: The clinical diagnosis of rheumatoid arthritis (RA) remains a challenge, making serological markers most interesting. The 2010 ACR/EULAR classification criteria for RA take into…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 13
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology